As the cold and flu season approaches, and COVID-19 continues to be present in the community, Emory health experts explain how to stay safe through important reminders about testing, vaccines, awareness and information about the new COVID-19 variant.
Emory computer scientist Ymir Vigfusson finds that cell phone data that is routinely collected by telecommunications providers can reveal changes of behavior in people who are diagnosed with a flu-like illness, while also protecting their anonymity.
A study from Emory Vaccine Center provides insights into why the boost in immunity from seasonal flu vaccination lasts for months but not years, unlike some childhood vaccinations.
A vaccine additive known as an adjuvant can enhance responses to a vaccine containing the exotic avian flu virus H5N1, so that both rookie and veteran elements of the immune response are strengthened, according to an Emory Vaccine Center study.
A 101-year-old resident of the Emory Healthcare skilled nursing center Budd Terrace at Wesley Woods has survived both Spanish flu as an infant and now COVID-19.
Drug Innovation Ventures at Emory is developing an antiviral compound, discovered here, that could potentially treat the new coronavirus currently spreading around the globe.
A $15.89 million NIAID contract will support Emory researchers as they move an investigational anti-influenza drug candidate into human testing.
Together with Mount Sinai, Emory will work to develop a life-saving universal flu vaccine as part of a new network of research centers created through the National Institutes of Health.
Scientists have identified a pair of molecules critical for T cells, part of the immune system, to travel to and populate the lungs. A potential application could be strengthening vaccines against respiratory pathogens such as influenza.
The Hope Clinic of the Emory Vaccine Center will enroll patients in an early-stage clinical trial evaluating two licensed seasonal influenza vaccines, administered with or without novel adjuvants for their safety and ability to generate an immune response.
Emory scientists have been probing the factors that limit reassortment between bird flu strains and a well-known strain (H3N2) that has been dominating the last few human flu seasons in the United States.
The National Academy of Inventors (NAI) has named Rafi Ahmed, PhD, as an NAI 2018 Fellow. Election to NAI Fellow status is a high professional distinction bestowed to academic inventors who have demonstrated a prolific spirit of innovation.
Vicki Hertzberg, PhD, professor at Emory's Nell Hodgson Woodruff School of Nursing and author of a recent study about disease transmission on airplanes, offers tips for healthy travel.
A recent study conducted by Emory's Nell Hodgson Woodruff School of Nursing and Georgia Tech assessed rates and routes of possible influenza or infectious disease transmission during flights.
The Emory Vaccine Center will participate in a new National Institutes of Health clinical trial testing an experimental vaccine to prevent H7N9 influenza virus infection.
Healthcare providers in Emory School of Medicine's Department of Emergency Medicine have led a robust response to the surge in influenza patients at Grady Memorial Hospital, using specialized trailers that have extended Grady's busy emergency department.
Emory Saint Joseph's infectious disease physician Mitchell A. Blass, MD discusses symptoms and tips for staying safe this season.
A multinational study that analyzed data from 47 countries over 15 years shows a worldwide increase in annual deaths caused by seasonal influenza-related respiratory illnesses.
A study of influenza vaccination in aging mice found microneedle patches more effective than standard immunization in overcoming reduced response to flu vaccine caused by statins.
Researchers found that small skin patches with dissolvable microneedles were safe and well-tolerated, generated robust immunity against influenza, could be self-administered and were strongly preferred over shots.
A component of the skin mucus secreted by South Indian frogs can kill the H1 variety of influenza viruses, researchers from Emory Vaccine Center and the Rajiv Gandhi Center for Biotechnology in India have discovered.
Advances in both light and electron microscopy are improving scientists¿ ability to visualize viruses such as HIV, respiratory syncytial virus (RSV), measles, influenza, and Zika in their native states.
Since its formation, the Emory Antibiotic Resistance Center has been battling a foe that threatens many of the modern miracles of medicine: the rise of bacterial strains resistant to multiple forms of antibiotics, including so-called "drugs of last resort."
Researchers at Emory Vaccine Center examine the precursors of memory B cells, called activated B cells, after influenza vaccination and infection and during Ebola virus infection.
Emory influenza researcher Richard Compans, PhD, recently delivered the annual Dean's Distinguished Faculty Lecture in Emory University School of Medicine.
What factors inhibit strong responses to seasonal flu vaccines in the elderly? Why do anti-flu antibodies last longer after vaccination in some people? Answers are emerging from an Emory University-based systems biology analysis of blood samples from more than 400 volunteers who received seasonal flu vaccines.
A new pair of studies published in the Journal of Infectious Diseases suggests that statins, drugs widely used to reduce cholesterol, may have a detrimental effect on the immune response to influenza vaccine and the vaccine's effectiveness at preventing serious illness in older adults.
A new clinical study at Emory University is testing whether microneedle patches applied to the skin may be a safe and effective alternative to conventional flu shots. The study is currently underway and enrolling volunteers.
Sparked by recent concerns about Ebola, an exhibit at Emory's Robert W. Woodruff Library examines the U.S. government's response to epidemics throughout American history.
A clinical trial of an H7N9 avian flu vaccine found a protective immune response in 59 percent of participants who received two injections along with an adjuvant.
Mice treated with antibiotics to remove most of their intestinal bacteria or raised under sterile conditions have impaired antibody responses to seasonal influenza vaccination. The findings suggest that antibiotic treatment before or during vaccination may impair responses to certain vaccines in humans, and may help to explain why immunity induced by some vaccines varies in different parts of the world.
To maximize vaccines' impact on global health, researchers and policymakers need to both develop new vaccines for additional diseases and improve their supply and delivery in developing countries, a review of vaccine development challenges in Science Translational Medicine argues.
Human volunteers immunized against the avian flu virus H5N1 readily developed antibodies against the stem region of the viral hemagglutinin protein.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded Emory University a contract to fund the Emory-UGA Center of Excellence for Influenza Research and Surveillance (CEIRS).
Researchers have found that people can successfully self-administer vaccines using microneedle skin patches.
Scientists at Emory Vaccine Center are taking steps toward building a "vaccine gene chip", by comparing the molecular signatures induced by five very different vaccines in the immune systems of human volunteers.
Researchers at Emory University and the Georgia Institute of Technology are investigating the benefits of a microneedle patch that will enable minimally trained personnel to deliver influenza and tetanus toxoid vaccines to the skin of pregnant women in developing countries.
Well-crafted messages about flu vaccination delivered through a message-framed, community-based approach, rather than through standard vaccination information sheets, could make it more likely for pregnant women in minority populations to plan immunizations for themselves and their infants.
After studying a busy emergency department (ED) for one year, researchers at Emory University have learned more about the spread of infection and why prevention strategies are so important.
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded Emory a contract to test new vaccines and therapies for infectious, immunologic and allergic diseases in adults and children.
Physician/researchers at Emory University and Children's Healthcare of Atlanta will begin testing a vaccine designed to protect against H7N9 influenza, the bird flu strain that caused severe illness and death in China last spring.
Scientists at Emory Vaccine Center have shown that an immune regulatory molecule called IL-21 is needed for long-lasting antibody responses in mice against viral infections.
Emory University Department of Medicine physicians, fellows, residents, and faculty will gather in Emory University Hospital auditorium Tuesday, March 13 from noon - 1 p.m. for a grand rounds discussion on this year's severe nationwide flu outbreak. Daniel Jernigan, MD, MPH, director of the influenza division at the Centers for Disease Control and Prevention (CDC), will lead the discussion on the deadly flu season, as well as the CDC's effort in understanding and detecting the virus.
Pregnant women who received the H1N1 influenza vaccine during the 2009 pandemic were less likely to have premature babies, and their babies weighed more on average.